A new study by the WHO experts proved the ineffectiveness of Remdesivir. Neither this drug, nor three others based on it, bring any benefit to reduce mortality from the coronavirus. Remdesivir turned out to be the first antiviral drug that the scientists paid attention to when developing methods to combat the coronavirus. Examining its potential, the experts from the World Health Organization have combined data from 405 hospitals in 30 countries around the world, in which over 11 thousand people were being treated for the COVID-19.
They were all randomly assigned to receive one of the four remdesivir-based drugs and other standard care that includes other drugs. These included remdesivir, the antimalarial drug hydroxychloroquine, the HIV drug lopinavir, and interferon-beta1a.
The results of the study were disappointing. None of the drugs showed any benefit in reducing coronavirus mortality. The experts say that other scientists will verify their research results, and some analyzes may still change during the peer review.
But it turned out that lopinavir, given in combination with ritonavir, a drug that increases the level of lopinavir in the human body, had no effect against the coronavirus.
David Brett-Major, a medical epidemiologist at the University of Nebraska Medical Center in Omaha, believes that a new research will only make it clear that the drugs previously focused on are not helping to treat the COVID-19.
The maximum benefit that has been observed in some cases with remdesivir is that the length of hospital stay is reduced by 4 days. But it did not show a tendency towards a decrease in mortality.
While remdesivir is still approved by the food and drug regulatory experts, it is used to treat many hospitalized patients.